Core Viewpoint - Rosen Law Firm is reminding investors who purchased Aldeyra Therapeutics, Inc. securities between November 3, 2023, and March 16, 2026, of the May 29, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Aldeyra securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is May 29, 2026, and a lead plaintiff acts on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding the clinical trials of reproxalap, an Aldeyra drug candidate, leading to unreliable positive findings [5]. - It is claimed that the inconsistency of trial results rendered the defendants' statements about Aldeyra's business and prospects materially false and misleading [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result [5].

Core Viewpoint - Aldeyra Therapeutics, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its drug candidate reproxalap during clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 3, 2023, to March 16, 2026, with a deadline for participation set for May 29, 2026 [2]. - The complaint alleges that Aldeyra's positive statements about its clinical trials were unreliable and that the results of reproxalap were inconsistent [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although such an appointment is not necessary to recover losses [2][3].

Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for securities fraud, with the Rosen Law Firm representing investors who purchased securities between November 3, 2023, and March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the Class Period, Aldeyra made false and misleading statements regarding the clinical trials of its drug candidate reproxalap, leading to unreliable positive findings [5]. - Investors who purchased Aldeyra securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action must move the Court by May 29, 2026, to serve as lead plaintiff, representing other class members in the litigation [3]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4].

Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. concerning allegations of securities fraud and unlawful business practices related to the company's investigational drug candidate reproxalap [2][4]. Group 1: Lawsuit Details - The class action lawsuit involves allegations that Aldeyra and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Aldeyra securities during the Class Period have until May 29, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: FDA Response and Stock Impact - On March 17, 2026, Aldeyra received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy [4]. - Following the announcement of the CRL, Aldeyra's stock price fell by $2.99 per share, or 70.69%, closing at $1.24 per share [4].

Core Viewpoint - A class action has been initiated against Aldeyra Therapeutics, Inc. due to alleged misleading statements regarding the efficacy of its drug product during the class period from November 3, 2023, to March 16, 2026 [1] Group 1: Legal Action - Investors are encouraged to contact the Portnoy Law Firm to discuss their legal rights and options for pursuing claims [2] - The deadline for investors to file a lead plaintiff motion is May 29, 2026 [1] Group 2: Clinical Trial Issues - The complaint alleges that Aldeyra failed to disclose inconsistencies in the results of the reproxalap clinical trials, rendering positive findings unreliable [3] - Defendants' statements regarding Aldeyra's business and prospects were claimed to be materially false and misleading [3] Group 3: Regulatory Response - On March 17, 2026, Aldeyra received a Complete Response Letter from the SEC, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [4] - The letter highlighted serious concerns about the reliability of the positive findings from clinical trials, stating that the totality of evidence does not support the product's effectiveness [4] - Following this announcement, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share [4]

Core Viewpoint - A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for failing to disclose critical information regarding clinical trial results, leading to significant stock price decline and investor harm [1][2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of Massachusetts on behalf of all individuals or entities that purchased Aldeyra securities between November 3, 2023, and March 16, 2026 [1]. - The complaint alleges that the defendants did not disclose that the results of the reproxalap clinical trials were inconsistent, rendering any positive findings unreliable [2]. Group 2: Impact on Stock Price - Following the revelation of the alleged failures to disclose, Aldeyra's stock price fell by $2.99, approximately 70.7%, closing at $1.24 per share on March 17, 2026 [3]. Group 3: Investor Actions - Investors who acquired shares of Aldeyra are encouraged to contact the law firm before the lead plaintiff motion deadline on May 29, 2026, to discuss their rights and interests regarding the class action [4].

Core Viewpoint - A securities fraud lawsuit has been filed against Aldeyra Therapeutics, Inc. following a significant drop in its stock price due to negative FDA feedback on its drug reproxalap for dry eye disease [1][2]. Group 1: Company Performance - Aldeyra Therapeutics' shares fell over 65% on March 17, 2026, after the company disclosed that the FDA issued a Complete Response Letter indicating that the application for reproxalap "failed to demonstrate efficacy in adequate and well controlled studies" [2]. - The FDA previously indicated that Aldeyra's New Drug Application (NDA) for reproxalap did not demonstrate efficacy in treating ocular symptoms associated with dry eyes and required at least one additional study to support its effectiveness [2]. Group 2: Investor Eligibility - Investors who purchased Aldeyra Therapeutics common stock between November 3, 2023, and March 16, 2026, and experienced a decline in their investment may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Legal Process - The deadline for investors to seek appointment as lead plaintiff in the lawsuit is May 29, 2026, and a class has not yet been certified [4]. - Investors who have lost money are encouraged to contact Block & Leviton for more information on their rights and options [4]. Group 4: Whistleblower Information - Individuals with non-public information about Aldeyra Therapeutics are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Aldeyra Therapeutics, Inc. securities, alleging misleading statements regarding the company's drug candidate, reproxalap, during the Class Period from November 3, 2023, to March 16, 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aldeyra's defendants made false and misleading statements about the clinical trial results of reproxalap, which were inconsistent and rendered positive findings unreliable [5]. - Investors who purchased Aldeyra securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the Aldeyra class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must move the Court by May 29, 2026, to represent other class members in the litigation [3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the FDA's Complete Response Letter indicating insufficient efficacy of its drug reproxalap for dry eye disease [1][3]. Group 1: Company Developments - Throughout 2024 and 2025, Aldeyra made optimistic forward-looking statements regarding the development and regulatory prospects of reproxalap, emphasizing its importance in the company's pipeline and commercial potential [2]. - The FDA issued a Complete Response Letter on March 17, 2026, stating that reproxalap had not demonstrated sufficient efficacy, contradicting the company's previous positive public statements about the drug's clinical data [3]. Group 2: Investigation Details - Levi & Korsinsky is investigating whether Aldeyra failed to disclose material information regarding efficacy risks that could have impacted the forward-looking statements made to shareholders [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Aldeyra Therapeutics, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the announcement of the Complete Response Letter, Aldeyra's stock price fell by $2.99 per share, representing a 70.7% decline, closing at $1.24 per share on March 17, 2026 [3]. Group 2: Legal Actions - Investors who purchased Aldeyra securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].